UK Markets open in 6 hrs 30 mins

Infinity Pharmaceuticals, Inc. (INFI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.1900+0.0200 (+1.71%)
At close: 04:00PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • g
    glenn
    To whatever divine spirit is out there: Throw us a bone with a price bounce. Or better yet, get Thomas in the role of lead biotech analyst at JP Morgan so people start paying attention to INFI'S potential.
  • T
    Thomas
    A few days ago I had an informative 50 minute Q&A with Dr. Larry Bloch, President of Infinity arranged by an analyst friend who was also on the call. I asked Dr. Bloch if he was aware of any drug that has been tested with Checkpoint Inhibitors that has shown a 50% or better improvement in OS. He said no, which was also my impression. Eganelisib has shown a 50% increase in OS in several studies with different cancers when added to a Checkpoint Inhibitor. This improvement in OS will likely be supported by additional longer term data from TNBC this fall. Its side effect profile on the 30 mg dose is also very acceptable. Since the mechanism of help with egan seems to be an increase in PD1 receptors, egan is well positioned to increase the anti tumor response in the roughly 80% of cancers that have low or negative PD1 receptors. The potential market is huge. GLTA longs.
  • T
    Thomas
    Some back of the envelop calculations for the future value of INFI. I assume that the probability of eganelisib eventually being FDA approved at around 70% based on OS benefit shown in multiple cancers in Phase 2 studies. Patents run until about mid 2030 but could be extended. I assume that the stock price will be about 5 X their income from sales of egan. Due to licensing and development agreements, I am assuming that INFI will receive about 1/3 of total sales of egan (this could be a larger share of revenues). Since Opdivo total sales are currently about $8 billion, I think it reasonable that egan will reach this figure in world wide sales. I also assume that over time, INFI new stock issuance will be about double the current number of shares. Here is the calculation of potential value of INFI with these assumptions. INFI income share at peak from egan will be about $2.67 billion. Assuming stock value at 5X annual income, net value of company would be about $13 billion. Discount by 1/3 due to new stock issuance, would mean we have to reduce the actual stock price by that amount. Multiply $13 billion by probability of FDA approval by .7 equals value of company at about $9 billion. Current value of company is $133 million. The company valued at 67X current stock price divided by 1/3 due to new stock issuance, gives a multiple of 22 over current price of 1.5 which gives a possible stock price of $33/share in 5 years or so. Open to any suggestions or comments on this analysis.
  • i
    itssofine2
    OK, it took a breather yesterday & this this morning and now its back.
    Let's see a strong close.
  • T
    Thomas
    My comment 14 days ago on my estimate of current value of share price by reducing share price by probability of certain events, assumed a number of events that need to happen. If in fact egan gets FDA approval as an improvement with checkpoint inhibitors, and if INFI never issues more shares, then a reasonable stock price within 5 years by my other assumptions in the post 14 days ago, gives an achievable share price of $140/share. Please refer to my older post for other assumptions such as share of sales going to INFI, etc.
  • J
    John
    I wonder how high it will go once they found partnership.
  • S
    Smitty
    Really wish this would make its way above $2! Need more volume and some positive momentum
  • C
    Chris
    By my count yesterday was the 10th consecutive day closing over $1...
  • M
    Michael
    The newest bull for Infinity is Anupam Rama at JPMorgan Chase unit JPMorgan. The prognosticator upped his recommendation on Infinity stock to overweight (buy) from his previous assessment of neutral, with a price target of $6 per share. Following the news about the urothelial cancer trial results, Wells Fargo analyst Nick Abbott moved his recommendation on Infinity from equal weight (neutral) to overweight (buy), and set a hefty price target of $14. Piper Sandler's Edward Tenthoff maintained his overweight recommendation while upping his price target from $7 to $8.

    Infinity Pharmaceuticals is a hot biotech issue at the moment. If eganelisib continues to perform well in clinical trials, there's probably more heat to come.
  • s
    simon
    INFI & ONCT on watch
  • G
    Gavin
    2B to 4.5B buyout is realistic.

    With the current market environment, and because they are downplaying this asset as on a “combination” asset, the street thinks between $6 - $9…I personally think a $16 price point is reasonable.
  • S
    Smitty
    Back to no volume - this stock is maddening. Message boards are dead, no volume...simply no interest at all.
  • T
    Thomas
    Just read the press release today. This stock should be $10 right now. The UC study at 2 years shows INFI drug egan approximately doubles overall survival with Opdivo compared to Opdivo alone in metas UC cancer patients. Company is in talks with pharma companies on co development. TNBC results toward the end of this year. GLTA longs.
  • J
    Joe
    Blackrock sold 4,3M shares in Q2, which was 64% of their holdings in Q1
  • G
    Gavin
    Pfizer has signed a definitive agreement to acquire all the outstanding shares of clinical-stage immuno-oncology company Trillium Therapeutics for a proposed equity value of $2.26bn, or $18.50 per share, in cash.
  • g
    glenn
    There's good premarket volume. it feels like we're back in the game.
  • T
    Tata
    This stock is heading north🤗
  • J
    J
    Just watched the Wainwright presentation and, again, confused by the decision to make TNBC the lead indication after all the development work and highlighting of bladder cancer as lead indication. Results of combination with Opdivo in UC look better than early data in TNBC… if those aren’t good enough, why should we expect TNBC will be different? Feels like a shell game. Stated reason for the decision was need to prioritize limited cash, but a) I don’t understand what looks so much better about TNBC that it deserves to be the priority and b) the limit3d cash issue looks silly when they are simultaneously pursuing new “platform” study in a range of solid tumors.
  • S
    Smitty
    Come on - lets break 1.60 and hold that level today!
  • J
    J
    And, again... looking at UC results and wondering why this indication is on the shelf in favor of spending precious money on early stage "platform" studies. Something doesn't make sense